Tg Therapeutics, INC. (TGTX) · 2026-10-30 · Daily technical & news analysis
Tg Therapeutics, INC. (TGTX) Technical Analysis — Chart, Levels & News
TGTX Daily Briefing: Fresh 52-Week Highs and Earnings Focus on 2026-10-30
ET · Stocks & ETFs
Information only. This page covers charts, levels, and news for context, not financial or trading advice.
Automated draft. Levels and signals are rules-based and use completed bars.
S&P 500 context: SPY -1.77% on 2026-10-30; this ticker +5.34% in the same completed session.
Next earnings: Nov 9, 2026
At a glance
- Trend
- Tg Therapeutics, INC. is above its 20-day (54.90), 50-day (55.33), and 200-day (43.81) averages. The trend reads up.
- Risk snapshot
- A typical day has moved about +3.86%% recently.
- Support below
- 58.00 | 55.66 | 54.90
- Resistance above
- Not enough completed bars for reliable levels.
What changed since the last close
- Set a new 52-week high
- Volume was 3.46× the 20-day average
Signal — short-term technical (daily chart)
On the short-term daily horizon, TGTX exhibits a bullish technical bias driven by strong upward momentum and sustained price action above the key moving averages. The lack of a detected candlestick pattern on the latest completed bar means price action provides no timing signal at this moment.
News, Macro & Industry Context
The medium-term narrative tone for TGTX is strongly positive, characterized by robust year-to-date gains, expansion of BRIUMVI use into new indications like myasthenia gravis and treatment-resistant schizophrenia, and rising investor focus on upcoming third-quarter 2026 results amid circulating buyout buzz. Broader healthcare sector momentum remains supported by strong corporate earnings across select biopharma peers, though macro conditions reflect volatile index trading and shifting sentiment across major equity benchmarks. Broad market participants continue to monitor support zones and broader macroeconomic index adjustments.
Catalysts
Upcoming catalysts include the projected third-quarter 2026 financial results expected on Monday, November 2, along with ongoing updates on clinical trial expansions.
Levels & Risk
Key support is defined by the Value Area Low at 41.38 alongside multiple Fair Value Gap zones spanning from 49.80 up to 58.00. The Volume Point of Control sits at 55.11, while resistance is established at the Value Area High of 59.10. Risk framing requires watching for any failure to hold near-term moving average supports, as macroeconomic volatility and broad market drawdowns could introduce sudden downside pressure.
Technical Breakdown
WaveTrend displays bullish momentum with the fast line above the slow line in mid-range. SMI is bullish and overbought above the signal line. Trend indicators show the price above the EMA20 confirming an uptrend bias, while the EMA5 above the EMA13 highlights short-term bullishness. Triggers indicate no fresh trigger bars. The candlestick pattern shows none detected on the latest completed bar. Higher timeframe analysis indicates no higher-timeframe extreme.
Learn the chart
Start with the question you have, not a trading strategy. Each guide explains one part of a ticker page in plain language.
Educational technical analysis. Not financial advice. Market data may be delayed or incomplete.